Drugs / AL002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05744401 | Jan 2023 → Jan 2025 | Alzheimer disease | Alector Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04592874 | Jan 2021 → Aug 2024 | Alzheimer disease | Alector Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03635047 Comparator | Nov 2018 → Aug 2020 | Alzheimer disease | Alector Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-07-30 | Alzamend Neuro, Inc. | Regulatory Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s alzamend.com ↗
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has submitted a pre-IND meeting request for AL002 and supporting briefing documents to the Center for Biological Evaluation and Research of the U.S. Food and Drug Administration. |
| 2021-07-23 | Alzamend Neuro, Inc. | Results Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease alzamend.com ↗
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (“ GLP ”) toxicology study using a transgenic mouse model of Alzheimer’s disease. |
| 2020-10-27 | Alzamend Neuro, Inc. | Results New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression alzamend.com ↗
The study, published in the Journal of Alzheimer’s Disease on October 15, 2020, shows that this novel vaccine, using immune cells known as dendritic cells loaded with a modified Aβ known as E22W42, could be a significant step in halting Alzheimer’s. |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03635047 ↗ |
| Action | Activate | “Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.” PMID 39444037 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2.” PMID 39444037 ↗ Oct 2024 |
| Route | Intravenous | “a single intravenous infusion of AL002” PMID 39444037 ↗ Oct 2024 |
| Target | TREM2 | “AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2.” PMID 39444037 ↗ Oct 2024 |